COSCIENS Biopharma Inc.

As of June 30, 2026, COSCIENS Biopharma Inc carries a market capitalization of 2.59M, placing it among publicly traded companies globally. Its enterprise value stands at -732,815.96, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

COSCIENS Biopharma Inc's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, COSCIENS Biopharma Inc has 376,882.70 shares outstanding.

As of June 30, 2026, COSCIENS Biopharma Inc trades at a trailing price-to-earnings ratio of 1.16. The price-to-sales ratio is 0.92, and the price-to-book ratio stands at 0.17.

As of June 30, 2026, COSCIENS Biopharma Inc maintains a current ratio of 4.33, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.18, indicating elevated leverage, while an interest coverage ratio of -21.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, COSCIENS Biopharma Inc posted a return on equity (ROE) of 59.74, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 28.24, measuring how efficiently the asset base is converted into earnings. The company generates approximately 267,096.77 in revenue per employee across its workforce of 31.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.25 indicates how many times COSCIENS Biopharma Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, COSCIENS Biopharma Inc recorded 10,000.00 in income tax expense. The company reported a pretax loss of -4.38M and 6.55M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 31, 2026, COSCIENS Biopharma Inc's stock has declined approximately 56.07% over the past 52 weeks. The 50-day moving average sits at 6.02, while the 200-day moving average is 6.42.

Over the twelve months ended June 30, 2026, COSCIENS Biopharma Inc generated 8.28M in revenue and converted that into 6.55M in net income, yielding earnings per share of -3.80. EBITDA reached -3.76M, while operating income came in at -4.70M.

As of June 30, 2026, COSCIENS Biopharma Inc holds 5.28M in cash and equivalents against 1.96M in total debt, resulting in a net debt position of -5.28M. Total book value stands at 14.84M, with working capital of 7.45M providing operational flexibility.

COSCIENS Biopharma Inc produced -3.72M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -256,000.00 in capital expenditures, free cash flow totaled -3.98M - equivalent to -3.60 per share.

Over the twelve months ended June 30, 2026, COSCIENS Biopharma Inc posted a gross margin of 45.41, reflecting its pricing power and cost economics. The operating margin of -56.80 and net profit margin of 79.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -50.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 9.27, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to COSCIENS Biopharma Inc shareholders.

COSCIENS Biopharma Inc's most recent stock split took place on July 7, 2026 with a 3:1 split ratio.

As of June 30, 2026, COSCIENS Biopharma Inc has an Altman Z-Score of -0.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.